You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

BTK Inhibition for B-Cell Malignancies

Read Overview

Supported by an independent educational grant from BeiGene

CME Activities

BTK Inhibitors in B-Cell Malignancies

What You Need to Know About BTK Inhibitors in B-Cell Malignancies

Resources

Steering Committee

Christian Buske, MD
Christian Buske, MD

Steering Committee Chair

Medical Director
Comprehensive Cancer Center Ulm
Institute of Experimental Cancer Research
University Hospital Ulm
Ulm, Germany

Shirley D’Sa, MD, FRCP, FRCPath
Shirley D’Sa, MD, FRCP, FRCPath

Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist and Associate Professor
Department of Hematology at UCL NHS Foundation Trust
London, United Kingdom

Barbara F. Eichhorst, MD
Barbara F. Eichhorst, MD

Associate Professor
Consultant Hematologist
Department for Internal Medicine
Secretary of the GLLSG
University Hospital of Cologne
Cologne, Germany

Constantine Tam, MD
Constantine Tam, MD

Head of Lymphoma Service,
Alfred Hospital
Professor of Haematology,
Monash University
Melbourne, Australia

Alessandra Tedeschi, MD
Alessandra Tedeschi, MD

Medical Director
Hematology Department
Niguarda Cancer Center
Milan, Italy

Steven Treon, MD, PhD
Steven Treon, MD, PhD

Professor
Harvard Medical School Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States

Matthew S. Davids, MD, MMSc
Matthew S. Davids, MD, MMSc

Clinical Research Director
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA